Dr. Reddy’s Laboratories Ltd. shares were in focus today after reports suggested that Indian bulk drug makers are preparing for the upcoming expiry of Novo Nordisk A/S’s patents on its blockbuster weight-loss drug Ozempic (semaglutide). According to Bloomberg, patents are set to lapse next year in several large markets, opening opportunities for generic players.
From leading firms like Dr. Reddy’s to suppliers such as Macleods Pharmaceuticals Ltd., companies are working to scale up production of semaglutide, the active pharmaceutical ingredient (API) that forms the base of Novo’s best-selling treatments — Ozempic for diabetes and Wegovy for obesity.
The preparations highlight India’s growing role in the global pharmaceutical supply chain, particularly in addressing demand for cost-effective versions of high-profile drugs as they lose exclusivity.
